- Home
- XAIR
XAIR
Beyond Air Inc.
as 12-18-2024 2:44pm EST
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | GARDEN CITY |
| Market Cap: | 33.6M | IPO Year: | N/A |
| Target Price: | $3.67 | AVG Volume (30 days): | 731.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $2.36 | Next Earning Date: | 02-10-2025 |
| Revenue: | $2,342,000 | Revenue Growth: | 685.91% |
| Revenue Growth (this year): | 230.8% | Revenue Growth (next year): | 265.55% |
Stock Insider Trading Activity of Beyond Air Inc. (XAIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lisi Steven A. | XAIR | CEO and Chairman of the Board | Sep 26 '24 | Buy | $0.50 | 1,476,626 | $744,662.49 | 3,249,411 | |
| Carey Robert | XAIR | Director | Sep 26 '24 | Buy | $0.50 | 1,476,626 | $744,662.49 | 1,476,626 |
Latest Beyond Air Inc. News
XAIR Breaking Stock News: Dive into XAIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
GlobeNewswire
16 days ago
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
GlobeNewswire
22 days ago
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board
GlobeNewswire
a month ago
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
a month ago
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GuruFocus.com
a month ago
Beyond Air Inc (XAIR) Q2 2025 Earnings Report Preview: What To Expect
GlobeNewswire
2 months ago
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
Compare XAIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XAIR Beyond Air Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.